Trump’s Drug Pricing Speech Breaks Little New Ground, Largely Spares Industry
From the article:
On Friday, President Donald Trump delivered a highly anticipated speech about drug pricing. The speech, coupled with the release of a “blueprint” providing more detail on the subject, was touted by administration officials as “the most comprehensive plan to tackle prescription drug affordability.”
But there was little in the President’s speech or in the blueprint that took direct aim at industry, despite the president’s tough talk against pharmaceutical company pricing practices. There were also very few new proposals in the speech and blueprint, as many of the strategies they advance were previously articulated in the President’s budget proposal or Council of Economic Advisors (CEA) white paper issued earlier this year (which I analyzed here).
Read the full artlce here!pharmaceuticals rachel sachs regulation